Questionnaire on knowledge about inflammation as a risk factor for cardiovascular diseases, on possible diagnosis, and management in the context of residual cardiovascular risk.

Questionnaire on knowledge about inflammation as a risk factor for cardiovascular diseases, on possible diagnosis, and management in the context of residual cardiovascular risk.

Dear Colleagues and Friends, We kindly invite you to complete a short questionnaire on knowledge about inflammation as a risk factor for cardiovascular diseases, on possible diagnosis, and management in the context of residual cardiovascular risk.https://ptlipid.pl/ankiety/how-important-is-inflammation-as-a-residual-cardiovascular-risk-factor-the-knowledge-perception-and-management/ The results of the questionnaire will help in planning educational activities and preparing a short, very practical Expert Document […]

Intensive Statin Therapy Versus Upfront Combination Therapy of Statin and Ezetimibe in Patients With Acute Coronary Syndrome: A Propensity Score Matching Analysis Based on the PL‐ACS Data

Intensive Statin Therapy Versus Upfront Combination Therapy of Statin and Ezetimibe in Patients With Acute Coronary Syndrome: A Propensity Score Matching Analysis Based on the PL‐ACS Data

Within the group of the recognized Polish experts, based on the data from the PL-ACS Registry, for the first time in the world we confirmed that the upfront combination lipid-lowering therapy is superior to statin monotherapy for all-cause mortality in patients with ACS. These results suggest that in high-risk patients, such an approach, rather than […]

Association between electronic nicotine delivery systems use and risk of stroke: a meta-analysis of 1,024,401 participants

Association between electronic nicotine delivery systems use and risk of stroke: a meta-analysis of 1,024,401 participants

Within LBPMC Group we also evaluated the relationship between electronic nicotine delivery systems (ENDS) use and the risk of stroke when compared to non-smokers. The results were presented at the ESC Congress in Amsterdam and published simultaneously in the Archives of Medical Science.  https://www.archivesofmedicalscience.com/Association-between-electronic-nicotine-delivery-systems-use-and-risk-of-stroke-a,171473,0,2.html 

New ILEP individual recommendations for patients with statin intolerance!

New ILEP individual recommendations for patients with statin intolerance!

Statins are a widely available, cheap, safe, and extremely effective means to reduce the cardiovascular disease (CVD) risk, and it is therefore a tragedy that these life-saving medicines are under-used. Non-adherence to statin therapy reaches up to 60% after 2 years, and cessation is associated with a significant increase in the risk of CVD events. Much of this […]

Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP)

Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP)

Abstract Statin intolerance is a clinical syndrome whereby adverse effects (AEs) associated with statin therapy [most commonly statin-associated muscle symptoms (SAMS)] result in the discontinuation of therapy and consequently increase the risk of adverse cardiovascular outcomes. However, complete statin intolerance occurs in only a small minority of treated patients (estimated prevalence of only 3–5%). Many […]

Red yeast rice for dyslipidaemias and cardiovascular risk reduction: A position paper of the International Lipid Expert Panel

Red yeast rice for dyslipidaemias and cardiovascular risk reduction: A position paper of the International Lipid Expert Panel

Abstract The risk of atherosclerotic cardiovascular disease (ASCVD) is strongly related to lifetime exposure to low-density lipoprotein (LDL)-cholesterol in longitudinal studies. Lipid-lowering therapy (using statins, ezetimibe and PCSK9 inhibitors) substantially ameliorates the risk and is associated with long-term reduction in cardiovascular (CV) events. The robust evidence supporting these therapies supports their continued (and expanding) role in risk reduction. In addition […]